Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) EBT Margin (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed EBT Margin for 6 consecutive years, with 759.97% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 77871.0% to 759.97% in Q3 2025 year-over-year; TTM through Sep 2025 was 246.43%, a 6699.0% decrease, with the full-year FY2024 number at 153.94%, up 34245.0% from a year prior.
  • EBT Margin was 759.97% for Q3 2025 at Ensysce Biosciences, down from 127.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 18.74% in Q3 2024 to a low of 3394.29% in Q2 2022.
  • A 5-year average of 782.29% and a median of 623.58% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: skyrocketed 523413bps in 2021, then plummeted -309667bps in 2022.
  • Ensysce Biosciences' EBT Margin stood at 128.68% in 2021, then crashed by -234bps to 429.24% in 2022, then plummeted by -58bps to 679.66% in 2023, then soared by 60bps to 275.17% in 2024, then crashed by -176bps to 759.97% in 2025.
  • Per Business Quant, the three most recent readings for ENSC's EBT Margin are 759.97% (Q3 2025), 127.87% (Q2 2025), and 149.37% (Q1 2025).